Proteomic Biomarkers In Drug Development

Biomarker (noun): Biomarkers are cellular, biochemical, or molecular alterations that are measurable in biological media such as human tissues, cells, or fluids. They indicate the presence of biological events or concerted events that are directly associated with a particular disease state.

Molecular Biomarkers (noun): Molecular biomarkers include proteins, carbohydrates, nucleic acids, and other compounds that provide insight into an individual’s health for screening risk factors, diagnosis, and prognosis. Molecular biomarkers are also extremely useful for drug discovery purposes.

Clinical Needs, Patient Perspective:
Am I at risk for cancer?
Is there anything I can do to alter the risk?
Do I have cancer?
Will my cancer respond to therapy?
Is my cancer responding to therapy?

Clinical Needs, Physician Perspective:
Identification of fingerprints associated with:

Prognosis at the time of diagnosis

Tumor responsiveness to therapy

Inter- and intratumor heterogeneity

Metastatic potential

Disease progression

CONTINUED: See Full PDF Document: Proteomic Biomarkers In Drug Development


Conclusions:
The study demonstrated efficacy of IND#70190 with overall improved performance scores and alleviation of asthma symptoms

Novel protein biomarkers for asthma and drug efficacy were identified

Drug effects are consistent with potent anti-inflammatory activity of IND#70190

Further clinical development and investigation of drug mechanism of action is warranted

A Proteomics Victory Over Cancer

04/14/07: Latest RCC Abstract

06/14/06: Our latest abstract

July 2005 our research in the battle against cancer won recognition in the scientific and pharmaceutical community to the extent that we have been presented on the cover of the July-August issue of " Cancer Genomics & Proteomics" , a journal published by the International Institute of Anticancer Research.

Novel natural products LP-01 and LP-02 developed by JBNI, were presented in cooperation with CTRC The Institute for Drug Development, San Antonio, TX at AACR-NCI-EORTC 2004: September 28-October 1, Geneva, Switzerland The AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, Discovery, Biology, and Clinical Applications was held in Geneva, Switzerland this past September. Our abstract on Serum Proteomic Biomarkers of a Natural Product in a Prospective Randomized Placebo-Controlled Clinical Trial in patients at risk for lung cancer was presented to the acclaim of the attendees.

In November of 2003, at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, Discovery Biology, and Clinical Applications held in Boston, Massachusetts, an abstract entitled "Serum Biomarkers of Natural Product Therapy in Human Lung Cancer Xenograft Models" was presented, demonstrating the efficacy of our novel entities (LP-01 and LP-02) in high-risk lung cancer patients.

read our report on Novel serum biomarkers for renal cell carcinoma